- JP-listed companies
- OncoTherapy Science, Inc.
- Financials
- FCF margin (%)
OncoTherapy Science, Inc. (4564)
Market cap
¥6.4B
P/E ratio
OncoTherapy Science develops cancer treatments using genetic research, including targeted drugs, immunotherapies, and precision medicine testing for personalized cancer care.
| Period End | FCF margin (%) | YoY (%) |
|---|---|---|
| Mar 31, 2025 | -108.7 | -46.11% |
| Mar 31, 2024 | -201.7 | +186.03% |
| Mar 31, 2023 | -70.5 | -67.85% |
| Mar 31, 2022 | -219.3 | -59.64% |
| Mar 31, 2021 | -543.4 | -28.61% |
| Mar 31, 2020 | -761.2 | -12.64% |
| Mar 31, 2019 | -871.3 | -46.57% |
| Mar 31, 2018 | -1,630.7 | +55.88% |
| Mar 31, 2017 | -1,046.1 | -7.24% |
| Mar 31, 2016 | -1,127.8 | +396.52% |
| Mar 31, 2015 | -227.1 |